Despite of the recent advances in regulatory T cell (Treg) therapy, a limited number of available cells and specificity at the desired tissue site have severely compromised their efficacy. Herein, an injectable drug-releasing (MTK-TK-drug) microgel system in response to stimulation by reactive oxygen species (ROS) was constructed with a coaxial capillary microfluidic system and UV curing. The spherical microgels with a size of 150 μm were obtained. The MTK-TK-drug microgels efficiently converted the pro-inflammatory Th17 cells into anti-inflammatory regulatory T cells (Treg) cells , and the ROS-scavenging materials synergistically enhanced the effect by modulating the inflammation microenvironment. Thus, the microgels significantly reduced cardiomyocyte apoptosis and decreased the inflammatory response in the early stages of post-myocardial infarction (MI) , thereby reducing fibrosis, promoting vascularization, and preserving cardiac function. Overall, our results indicate that the MTK-TK-drug microgels can attenuate the inflammatory response and improve MI therapeutic effects .

中文翻译：

---

ROS响应药物释放注射微凝胶用于改善心肌梗死

尽管调节性 T 细胞 (Treg) 疗法最近取得了进展，但可用细胞数量有限以及所需组织部位的特异性严重影响了其疗效。在此，通过同轴毛细管微流体系统和紫外线固化构建了响应活性氧（ROS）刺激的可注射药物释放（MTK-TK-药物）微凝胶系统。得到尺寸为150μm的球形微凝胶。 MTK-TK药物微凝胶有效地将促炎性Th17细胞转化为抗炎性调节性T细胞（Treg）细胞，ROS清除材料通过调节炎症微环境协同增强效果。因此，微凝胶显着减少心肌梗塞后早期的心肌细胞凋亡并降低炎症反应，从而减少纤维化，促进血管化，保护心脏功能。总的来说，我们的结果表明 MTK-TK-药物微凝胶可以减轻炎症反应并提高 MI 治疗效果。